2024 ANNUAL MEETING OF STOCKHOLDERS CHAIR'S ADDRESS

15 May 2024 – Melbourne, Australia (**14 May 2024** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) is pleased to provide the Chair's address to be delivered at the 2024 Annual Meeting of Stockholders today.

The Annual Meeting will be held as a virtual meeting, details of which are provided below:

Date:	Tuesday, 14 May 2024 at 5:00pm Minneapolis Time or Wednesday, 15 May 2024 at 8:00am Sydney Time
URL:	meetnow.global/MP2YNVQ

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

IMRICOR MEDICAL SYSTEMS INC.

2024 ANNUAL MEETING OF STOCKHOLDERS

CHAIR'S ADDRESS

I recently presented our first quarter results, at which time I outlined in detail what a great start 2024 is off to and how we are succeeding across all aspects of our business. I won't go through that again today, but you can find a video recording of the briefing on the Imricor website if you missed it.

For today's meeting, I'd just like to give a brief overview of where we stand now and what our priorities are for the year ahead.

Before I do, I've been reminding people recently that we didn't develop this technology for the fun of it, just to have to search for a medical application. The medical community, itself, wanted to perform ablations for ventricular tachycardia (VT) and atrial fibrillation (AF) guided by real-time MRI for reasons exhaustively researched and published in the 2000's. All we did at Imricor is deliver the MRI compatible devices that make this desire a reality. I say "all we did," but in fact, as you know, we were the last ones to try and the only ones to succeed in this task.

Because of our success, we are giving rise to a new field and a new kind of interventional lab, what the industry now calls iCMR, which stands for interventional cardiac magnetic resonance. The field of iCMR encompasses any interventional cardiology procedure performed under MRI guidance, and an iCMR lab is simply an interventional lab that houses an MRI system for imaging, instead of an x-ray fluoroscopy system.

Coming back to where we stand now… following the pandemic, we found ourselves well positioned to advance the field of iCMR because we completed the required product development to grow beyond atrial flutter ablations and into complex ablations, like the ones I mentioned a second ago, VT and AF – procedures where we believe MRI will add the most benefit and the most value for patients, physicians, and hospitals.

With product development behind us, for a whole platform of disposable devices and capital equipment, we set out in 2023 to advance the clinical trial strategies that would allow us break into the US market and expand our indications to VT in Europe.

At the same time, we re-engaged our customer base in 2023, working with each site to start or restart their iCMR programs that were originally planned for 2020 before the pandemic hit. As they are getting restarted in 2024, the feedback has been very positive, and the doctors could not be happier with the benefits MRI brings to this field.

Here's what Dr. Marco Götte at Amsterdam UMC said after restarting cases there in April, using our landmark NorthStar 3D mapping system.

Now in 2024, we have clear priorities to drive this business to the next level and take advantage of the launching pad we built in 2023 and in all the years before. That's where we are today.

Looking to the year ahead, first in 2024, we are going to commence our two clinical trials: VISABL-AFL for FDA approval, and VISABL-VT for expanding our indications to VT. The first quarter was very productive in these areas, and now, in the present quarter, we expect to kick off both trials. The VISABL-AFL trial is huge because it opens the door for FDA approval, while

the VISABL-VT trial is a landmark event that will comprise several first-in-man breakthroughs (and certainly several publications and presentations). We believe the start of VT ablations guided by real-time MRI will be a very significant catalyst to the field, because we are finally delivering on the promise of MRI guidance for complex ablations – a dream dating back to the mid-90's.

It is also important for us in 2024 to establish consistent atrial flutter procedure volumes at each of our active customer sites and then steadily grow the number of actives sites throughout the year. Every one of these active sites will provide immediate revenue for Imricor, but more importantly, will also form the installed base for VT and AF ablations in the future.

In addition to site activation, we want to continue building the sales pipeline of new sites that will become active next across Europe, the Middle East, and (pending TGA approval) Australia and New Zealand.

I'm pleased to say that we are doing exactly what we wanted to do across all these commercialization efforts, and we have a clear path ahead of us to continue to do so.

I would like to take a moment in closing to thank and acknowledge team at Imricor. I am so fortunate to work with some of the best talent in the field. I've asked a lot of them over the past couple of years and they have delivered. Living in the twin cities, with medical device giants like Medtronic, Abbott, and Boston Scientific, as well as countless start-ups, these are people who have choices about where they work, and it is a testament to the significance of what we're doing together that we are all so dedicated to our mission of growing iCMR to be a new standard of care.

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is a leading developer of innovative MRI-compatible medical devices which can be used to carry out real-time iCMR cardiac ablation procedures. Headquartered in the US, Imricor seeks to make a meaningful impact on patients, healthcare professionals, and healthcare facilities around the world by increasing the success rates and bringing down the overall costs of cardiac ablation procedures.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union and the Kingdom of Saudi Arabia (KSA) with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in Australia, the U.S., and the other Middle East countries.

The Company has also obtained approval within the EU and KSA for the sale of the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter (pending in KSA) and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE HealthCare help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.